Jump to content

Cancer Diagnostic Probe

From Wikipedia, the free encyclopedia

The Cancer Diagnostic Probe (CDP) is a medical device used in Iran during breast cancer surgery.[1][2] First developed by Nano Hesgar Sazan Salamt Arya, an Iranian company,[1] CDP has received medical approval in Iran, where it is used in surgical centers.[2]

Development and application

[edit]

The Cancer Diagnostic Probe was developed by a team led by Mohammad Abdolahad, a 2019 Mustafa Prize laureate and faculty member of the School of Electrical and Computer Engineering at the University of Tehran, to facilitate the determination of cancerous margins.[2] Abdolahad stated that the clinical trial for the device lasted 4 years and that up to 500 surgeries had been carried out using the CDP by 2020.[2] According to Sayyed Ruhollah Miri, the head of the Cancer Institute at the Tehran University of Medical Sciences, the CDP reduces the diagnosis time to 1–2 minutes.[3]

Mechanism

[edit]

The CDP device is composed of three main parts: "a disposable sensor; a wireless electrical head probe used by the surgeon; [and] a main control computer system which receives the signals from the head probe".[2] It electrochemically measures the hypoxia glycolysis metabolism in real-time "in pre-cancerous and cancerous lesions in cavity side margins".[1] It measures the release of H2O2 from cancer or atypical cells by the reverse Warburg effect.[1][4]

Reception

[edit]

The development of CDP was supported by the Iranian Nano Technology Development Headquarters.[3] After receiving medical approval, this system has been used in breast cancer surgeries in Iran.[2] As of 2022, four U.S. patents have been published related to CDP.[5]

References

[edit]
  1. ^ a b c d "Real-time Cancer Diagnostic Probe – Iran Advanced Clinical Training Center". Tehran University of Medical Sciences. Archived from the original on 14 January 2023. Retrieved 10 January 2023.
  2. ^ a b c d e f "Mustafa (pbuh) Prize laureate presented his Cancer Diagnostic Probe". Mustafa Prize. Archived from the original on 14 January 2023. Retrieved 10 January 2023.
  3. ^ a b "The visit of a delegate of Indian businessmen and doctors to the achievement of Iranian researchers in the treatment of breast cancer". Iranian nanotechnology newsletter (in Persian). 9 January 2023. Archived from the original on 14 January 2023. Retrieved 12 January 2023.
  4. ^ Dabbagh, Najmeh; Abbasvandi, Fereshteh; Miripour, Zohreh Sadat; et al. (2022). "Accuracy of cancer diagnostic probe for intra‐surgical checking of cavity side margins in neoadjuvant breast cancer cases: A human model study". The International Journal of Medical Robotics and Computer Assisted Surgery. 18 (1): e2335. doi:10.1002/rcs.2335. ISSN 1478-5951. PMID 34571582. S2CID 238204138. Archived from the original on 14 January 2023. Retrieved 14 January 2023.
  5. ^ Miripour, Zohreh Sadat; Abbasvandi, Fereshteh; Aghaee, Parisa; et al. (2022). "Human study on cancer diagnostic probe (CDP) for real-time excising of breast positive cavity side margins based on tracing hypoxia glycolysis; checking diagnostic accuracy in non-neoadjuvant cases". Cancer Medicine. 11 (7): 1630–1645. doi:10.1002/cam4.4503. ISSN 2045-7634. PMC 8986141. PMID 35224879.